MedTrace Logo

Describing the Effects of Insoles in Children With Increased Femoral Anteversion and Pes Planovalgus

NCT03812822 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2020-03-13

No results posted yet for this study

Summary

Increased Femoral Anteversion is a transverse plan problem that affects lower body alignment, walking and standing characteristics and also pes planovalgus mostly accompanies with IFA. It is shown that children with IFA and PPV have back and leg pain, fatigue, muscle cramps and they are under the risk for chronic disorders such as osteoarthritis, scoliosis and muscle injuries.

Insoles, which reduce pronation of foot (flat foot), provide apparently a static correction by supporting proper alignment in children with IFA and PPV. However, the dynamic effects of insoles to lower extremity biomechanics while walking is not known.

The aims of this study are to determine the effects of the insoles on walking biomechanics in children with IFA and PPV by comparing with their healthy peers.

Conditions

  • Femoral Anteversion
  • Pes Planovalgus
  • Flat Foot

Interventions

DEVICE

Insole

Custom-made insoles which support the foot at subtalar neutral position

Sponsors & Collaborators

  • Istanbul Kültür University

    lead OTHER

Principal Investigators

  • Halenur Evrendilek, GRAD ASST · İstanbul Kültür University

  • Ekin Akalan, PROF · İstanbul Kültür University

  • Miray Budak, ASST PROF · İstanbul Medipol University

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
8 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-12-24
Completion
2019-12-24

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03812822 on ClinicalTrials.gov